



Combat Drugs Limited

Regd. Off: 4th Floor, Plot No. 94,
Sagar Society, Road No.2,
Banjara Hills, Hyderabad – 500 034
D.L.No.TG/15/04/2016-14766 /14767

Works: 9-109/9, Plot No.112,
Road No. 14, Gayatri Nagar,
Bouduppal, Hyd - 500039, T.S
CIN No.L24230TG1986PLC006781

Ph: (+91)-40-48536100
Url: www.combatdrugs.in
Email: info@combatdrugs.in
GST: 36AAACC8372L1ZB

12th August, 2019

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Proposal for Takeover of Limited Liability Company in the USA

The Board of Directors of the company at its meeting held today, 12th August, 2019, have considered the proposal for acquisition of a Limited Liability Company (LLC) (hereinafter referred to as the "Target Company") based in the United States of America.

The target company is operating in the field of Information Technology Services specializing in ERP Solutions, Business Intelligence, Data Warehousing, Software Development, Consulting, Programming and Offshore Development, having an Income Revenue of USD \$11.86 Million (*approx Rs.81.83 Crores at Rs.69.00 per US dollar*) and a Gross Profit of USD \$0.773 Million (*approx Rs.5.33 Crores at Rs.69.00 per US dollar*) as of their Financial Year ended 31st December, 2018. The Target company has clients in Healthcare, Hospitality, Financial services etc ranging from small businesses to Fortune 1000 companies including clients such as Merck, Allregan, Bank of America, SAP, IBM, among others.

The Board with a view of making the company's global presence in the field of Pharma and Information Technology, is considering the proposal of the acquisition of the target company, subject to Due Diligence of the Target company and its authorized representatives and the Feasibility and Viability report.

The Board has authorized its Promoter Mr. Janakiram Ajarapu and/or its Director/s to conduct and/or appoint an agency for the Feasibility and Technical and Financial Due Diligence of the project and detailed discussions with the Promoters of the target company and their bankers, Creditors and Debtors thereof and making representations, for obtaining statutory approvals, wherever necessary.

The Board also considered the proposal for the change of the Company's name to bring it in sync with the diversified interests of the company. The Board will put forth the same, in the ensuing Annual General Meeting for the approval of the Shareholders of the company along with other relevant proposed resolutions and, for submission of other necessary approvals.

We kindly request you to take the above said on record in compliance with the applicable Regulations including the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Thanking You,
Yours Sincerely,
For **COMBAT DRUGS LIMITED**

Kumar Raghavan

COMPANY SECRETARY & COMPLIANCE OFFICER

